Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells

Annals of Oncology

Volumn 9, Issue SUPPL. 5, 1998, Pages

  Rooney, C M ^a,e   Roskrow, M A ^b   Suzuki, N ^c   Ng, C Y C ^d   Brenner, M K ^a   Heslop, H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Cytotoxic T lymphocyte (CTL); Dendritic cell; EBV associated lymphoproliferative disease (EBV LPD); Epstein Barr virus (EBV); Gene transfer; Gene marking; Hodgkin's disease; Immunotherapy; Latent membrane protein 2 (LMP2)

Indexed keywords

MEMBRANE PROTEIN;

ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; GENE TRANSFER; HODGKIN DISEASE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MARKER GENE; PRIORITY JOURNAL;

EID: 0032448280     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/9.suppl_5.S129     Document Type: Conference Paper

References (15)

1. Heslop HE, Ng CYC, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med 1996; 2: 551-5.
2. Rooney CM, Smith CA, Ng CYC et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
3. Roskrow MA, Suzuki N, Gan YJ et al. EBV-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998 (in press).
4. Smith CA, Ng CYC, Heslop HE et al. Production of genetically modified EBV-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 1995: 473-9.
5. Rooney CM, Loftin SK, Holladay MS et al. Early identification of Epstein-Barr virus-associated post-transplant lymphoproliferative disease. Br J Haematol 1995; 89: 98-103.
6. Beaty O, Hudson MM, Greemvald C et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol 1995; 13: 603-9.
7. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993; 11: 1208-15.
8. Rubin B, Martin EPG, Arnaud J et al. Expression and signnal transduction of T-cell antigen receptor (TCR)/CD3 complexes on fresh or in vitro expanded T lymphocytes from patients with Hodgkin's disease and non-Hodgkin's lymphomas. Scand J Immunol 1997; 45: 715-25.
9. Rickinson AB, Moss DJ. Human cytoto.xic T lymphocyte responses to Epstein-Barr virus infection. Ann Rev Immunol 1997; 15:405-31.
10. Levitskaya H, Coram M, Levitsky Vet al. Inhibition of antigen processing by the internal repeat of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685-8.
11. Khanim F, Yao QY, Niedobitck G et al. Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood 1996; 88: 3491-501.
12. Lee SP, Tierney RJ, Thomas WA et al. Conserved CTL epitopes within the latent membrane protein 2. J Immunol 1997; 158: 3325-34.
13. Hart DNJ. Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood 1997; 90 (9): 3245-87.
14. Romani N, Gruner S, Drang D et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180: 83-93.
15. Chuck AS, Palsson BO. Consistent and high rates of gene transfer can be obtained using flow-through transduction over a wide range of retroviral titers. Hum GeneTher 1996; 7: 743-50.